Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy

Table 1 Baseline patient characteristics, mean ± SD/n (%)

Characteristic	Value
Mean age	74 ± 9.5
Mean BMI	27.60 ± 5.36
Stage 2 disease (n = 120)	20 (16.67)
Stage 3 disease (n = 120)	25 (20.83)
Stage 4 disease (n = 120)	75 (62.5)
Percent mCSPC from stage 4 (n = 75)	47 (63.4)
Percent mCRPC from stage 4 (n = 75)	28 (36.6)
Hispanic (n = 120)	23 (19)
Asian (n = 120)	25 (20.7)
Non-Hispanic White (n = 120)	69 (57)
Black (n = 120)	4 (3.3)
Median serum vitamin D level (ng/mL)	35.4 (7.8-120)
Vitamin D deficiency at diagnosis (%) (< 20 ng/mL)	12.50

BMI: Body mass index; mCSPC: Metastatic castration-sensitive prostate cancer; mCRPC: Metastatic castration-resistant prostate cancer.